This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Bio-Techne (TECH) and Agilent (A)

Tipranks - Tipranks - Fri May 29, 9:32AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Quanterix (QTRX), Bio-Techne (TECH) and Agilent (A).

Memorial Day Sale – Claim 70% Off TipRanks

Quanterix (QTRX)

In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Quanterix, with a price target of $4.00. The company’s shares closed last Thursday at $3.03.

According to TipRanks.com, CFA is a 2-star analyst with an average return of 0.6% and a 37.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Tempus AI, Inc. Class A, and Pacific Biosciences. ;'>

Currently, the analyst consensus on Quanterix is a Hold with an average price target of $4.00, implying a 49.8% upside from current levels. In a report released yesterday, TipRanks – Anthropic also upgraded the stock to Hold with a $2.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Bio-Techne (TECH)

Citi analyst Patrick B Donnelly maintained a Buy rating on Bio-Techne today and set a price target of $70.00. The company’s shares closed last Thursday at $49.62.

According to TipRanks.com, Donnelly is a 3-star analyst with an average return of 1.9% and a 45.2% success rate. Donnelly covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Fortrea Holdings Inc. ;'>

Bio-Techne has an analyst consensus of Moderate Buy, with a price target consensus of $59.25, representing a 22.5% upside. In a report issued on May 14, RBC Capital also initiated coverage with a Buy rating on the stock with a $62.00 price target.

Agilent (A)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Agilent today and set a price target of $170.00. The company’s shares closed last Thursday at $134.41.

According to TipRanks.com, Arias is a 2-star analyst with an average return of 0.6% and a 43.2% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, BillionToOne, Inc. Class A, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Agilent is a Strong Buy with an average price target of $157.62, a 18.5% upside from current levels. In a report issued on May 26, RBC Capital also initiated coverage with a Buy rating on the stock with a $153.00 price target.

Read More on QTRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).